FUTU vs. ADMA
FUTU (Futu Holdings Limited) and ADMA (ADMA Biologics, Inc.) are both stocks. FUTU operates in Capital Markets (Financial Services), while ADMA operates in Biotechnology (Healthcare). Over the past 5 years, FUTU returned -6.95%/yr vs 35.16%/yr for ADMA. At a 0.23 correlation, their price movements are largely independent.
Performance
FUTU vs. ADMA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, FUTU achieves a -39.65% return, which is significantly higher than ADMA's -54.99% return.
FUTU
- 1D
- 2.10%
- 1M
- -31.67%
- YTD
- -39.65%
- 6M
- -42.20%
- 1Y
- -13.16%
- 3Y*
- 34.68%
- 5Y*
- -6.95%
- 10Y*
- —
ADMA
- 1D
- -1.32%
- 1M
- -3.41%
- YTD
- -54.99%
- 6M
- -58.49%
- 1Y
- -61.99%
- 3Y*
- 27.09%
- 5Y*
- 35.16%
- 10Y*
- 1.84%
FUTU vs. ADMA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
FUTU Futu Holdings Limited | -39.65% | 105.29% | 49.87% | 34.39% | -6.12% | -5.36% | 343.31% | -30.08% |
ADMA ADMA Biologics, Inc. | -54.99% | 6.36% | 279.42% | 16.49% | 175.18% | -27.69% | -51.25% | 1.27% |
Correlation
The correlation between FUTU and ADMA is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.09 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.18 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since Mar 8, 2019 | 0.23 |
The correlation between FUTU and ADMA shifts across timeframes, from 0.09 (1 year) to 0.23 (all time), reflecting how their relationship changes across market environments.
Fundamentals
FUTU:
$13.82B
ADMA:
$1.97B
FUTU:
HK$71.05
ADMA:
$0.68
FUTU:
10.76
ADMA:
12.13
FUTU:
4.50
ADMA:
3.93
FUTU:
2.63
ADMA:
5.05
FUTU:
HK$24.01B
ADMA:
$509.86M
FUTU:
HK$21.07B
ADMA:
$312.42M
FUTU:
HK$14.81B
ADMA:
$218.74M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
FUTU vs. ADMA — Risk / Return Rank
FUTU
ADMA
FUTU vs. ADMA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Futu Holdings Limited (FUTU) and ADMA Biologics, Inc. (ADMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| FUTU | ADMA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.93 | ||
| Sortino ratioReturn per unit of downside risk | +1.96 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 0.76 | +0.26 |
| Calmar ratioReturn relative to maximum drawdown | -0.24 | -0.98 | +0.74 |
| Martin ratioReturn relative to average drawdown | -0.64 | -1.95 | +1.31 |
Loading charts...
Drawdowns
FUTU vs. ADMA - Drawdown Comparison
The maximum FUTU drawdown since its inception was -87.23%, roughly equal to the maximum ADMA drawdown of -91.28%. Use the drawdown chart below to compare losses from any high point for FUTU and ADMA.
Loading charts...
Drawdown Indicators
| FUTU | ADMA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.23% | -91.28% | +4.05% |
Max Drawdown (1Y)Largest decline over 1 year | -54.18% | -63.48% | +9.30% |
Max Drawdown (3Y)Largest decline over 3 years | -54.18% | -68.99% | +14.81% |
Max Drawdown (5Y)Largest decline over 5 years | -86.42% | -68.99% | -17.43% |
Max Drawdown (10Y)Largest decline over 10 years | — | -86.11% | — |
Current DrawdownCurrent decline from peak | -50.21% | -66.50% | +16.29% |
Average DrawdownAverage peak-to-trough decline | -47.53% | -53.05% | +5.52% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.61% | 33.85% | -13.24% |
Volatility
FUTU vs. ADMA - Volatility Comparison
Futu Holdings Limited (FUTU) has a higher volatility of 39.14% compared to ADMA Biologics, Inc. (ADMA) at 9.74%. This indicates that FUTU's price experiences larger fluctuations and is considered to be riskier than ADMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| FUTU | ADMA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 39.14% | 9.74% | +29.40% |
Volatility (6M)Calculated over the trailing 6-month period | 51.00% | 45.54% | +5.46% |
Volatility (1Y)Calculated over the trailing 1-year period | 63.08% | 54.60% | +8.48% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 72.75% | 59.47% | +13.28% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 75.16% | 69.03% | +6.13% |
Dividends
FUTU vs. ADMA - Dividend Comparison
FUTU's dividend yield for the trailing twelve months is around 2.67%, while ADMA has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 |
|---|---|---|---|
ADMA ADMA Biologics, Inc. | 0.00% | 0.00% | 0.00% |
FUTU Futu Holdings Limited | 2.67% | 0.00% | 2.50% |
Financials
FUTU vs. ADMA - Financials Comparison
This section allows you to compare key financial metrics between Futu Holdings Limited and ADMA Biologics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
FUTU vs. ADMA - Profitability Comparison
FUTU - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Futu Holdings Limited reported a gross profit of 5.11B and revenue of 5.86B. Therefore, the gross margin over that period was 87.2%.
ADMA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a gross profit of 80.75M and revenue of 114.49M. Therefore, the gross margin over that period was 70.5%.
FUTU - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Futu Holdings Limited reported an operating income of 3.53B and revenue of 5.86B, resulting in an operating margin of 60.3%.
ADMA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported an operating income of 58.27M and revenue of 114.49M, resulting in an operating margin of 50.9%.
FUTU - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Futu Holdings Limited reported a net income of 850.55M and revenue of 5.86B, resulting in a net margin of 14.5%.
ADMA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a net income of 45.33M and revenue of 114.49M, resulting in a net margin of 39.6%.
Frequently Asked Questions
FUTU and ADMA have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
FUTU has higher volatility (39.14%) compared to ADMA (9.74%). In terms of maximum drawdown, FUTU dropped -87.23% vs ADMA's -91.28%.
FUTU currently has the higher Sharpe Ratio (-0.21 vs -1.14), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for FUTU and ADMA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer